Propafenone and amiodarone efficacy in paroxysmal atrial fibrillation treatment

• Main Authors: N. N. Isakova, Yu. V. Kulakov, A. M. Kononova, O. P. Modnova, L. M. Moldovanova, O. A. Moldovanova
• Format: Article
• Language: Russian
• Published: «FIRMA «SILICEA» LLC 2006-06-01
• Series: Российский кардиологический журнал
• Subjects: paroxysmal atrial fibrillation; heart failure; treatment efficacy; propafenone; amiodarone
• Online Access: https://russjcardiol.elpub.ru/jour/article/view/1840
• ISSN: 1560-4071; 2618-7620

To assess antiarrhythmic efficacy of propafenone and amiodarone in paroxysmal atrial fibrillation (AF) treatment, 204 patients (125 males, 79 females, aged 57-72 years) with various stages of heart failure (HF) were examined. Group I (HF of 0-I Functional Class, FC; n = 72) received propafenone (Propanorm, PRO. MED. CS Praha): load dose 600 mgper os, plus 300 mg 12 hours later. Group II (HFof II-III FC; n = 132) received amiodarone, 1200 mgper os, 450 mg intravenously, then - according to standard scheme. Propafenone terminated AF paroxysm in 83, 3 % of cases, amiodarone - in 78, 6 %. Inpatients without severe structural and functional myocardial changes and HF of 0-I FC, propafenone was most effective during the first 24 hours (70,8 %). In patients with severe structural myocardial changes and HF of II-III FC, maximal number of patients with rhythm restored by amiodarone was registered after 7 days of the treatment. Propafenone didn't cause any adverse hemodynamic effects inpatients with HF ofl FC. Propafenone and amiodarone combination potentiated antiarrhythmic effects in AF.